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1. Fearon WF, Yong AS, Lenders G, et al. The impact of downstream coronary
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1840–7.REPLY: True Fractional Flow Reserve of
Left Main Coronary Artery Stenosis in the
Presence of Downstream Coronary StenosesWe would like to thank Dr. Saito for his interest in our
study (1) evaluating the inﬂuence of a downstream
epicardial stenosis on the fractional ﬂow reserve
measurement of an intermediate left main stenosis
with the pressure wire positioned in the nondiseased
contralateral vessel. We agree with Dr. Saito that the
ﬁndings are in accordance with mathematical equa-
tions like the one he proposes and the one we have
previously published, which demonstrated our un-
derstanding of the background mechanism (2). Un-
fortunately, these equations and the even more
complex one proposed for the case in which both
downstream vessels are diseased suffer from the
major limitation that they assume the microvascular
resistance in each downstream vessel. Moreover, as
was the case with the equations proposed for evalu-
ating the individual fractional ﬂow reserve values of
serial stenoses (3,4), their complexity makes it un-
likely that a practicing interventional cardiologist will
apply them clinically. We are pleased that Dr. Saito’s
letter highlights the practical message of our paper,
that the effect of downstream epicardial disease on
the functional assessment of intermediate left
main disease with the pressure wire in the non-
diseased downstream epicardial vessel is small and
clinically irrelevant, unless the downstream disease is
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Balloons in Bifurcations
The Remaining Variable to Fit the
Perfect EquationWe have read with great interest and satisfaction
the elegant paper written by Kim et al. (1) and the
editorial by Abdel-Latif et al. (2); we want to
congratulate the authors on the original design of
these 2 trials. As occurs with chronic total occlu-
sions and left main disease, bifurcation lesions
represent a constantly debated issue in all the
meetings of Interventional Cardiology, and despite
the large number of trials and the different tech-
niques tested, there still exist unresolved aspects in
the treatment of this subset of patients. To date,
none of the dedicated stent platforms has shown
relevant advantages over the conventional drug-
eluting stents (DES) because of their higher pro-
ﬁle, the complexity of utilization, or the need for
additional stents, and although there is a general
agreement supported by previous trials that provi-
sional stenting is the best choice, there is still sig-
niﬁcant heterogeneity, and different techniques are
widely used, such as crush, T-stenting, modiﬁed T-
stenting, culotte, and a large list of the mentioned
dedicated stents and techniques. The data provided
by these 2 trials with 54% of second-generation DES
in the CROSS (Choice Of Optimal Strategy For
Bifurcation Lesions With Normal Side Branch) and
37% in the PERFECT (Optimal Stenting Strategy For
True Bifurcation Lesions) trials show us the best
paths to face against these challenging lesions in
the following years. Second-generation stents have
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of their better results, drawing the meaningful
conclusion that the treatment of bifurcation lesions
has become a much easier procedure because,
seemingly, the complex strategies add no advan-
tages over provisional stenting, and the role of a
previously considered mandatory technique, despite
being technically demanding, that is, the ﬁnal
kissing balloon inﬂation, nowadays is only neces-
sary in selected cases. Moreover, there are also
reasons for the optimism because there may exist
room for improvement because the third-generation
DES without polymer or with biodegradable ones
may behave even better. In our opinion, we are
really close to reaching the perfect knowledge in
the treatment of bifurcations. However, we believe
that one remaining question is still unanswered:
previous reports have demonstrated the ability of
drug-eluting balloons to diminish the restenosis
rate in the origin of the side branch (3,4), which is
the Achilles’ heel of these lesions. With the back-
ground information provided by the CROSS and
PERFECT studies in hand, we believe that the only
remaining question would be to clarify whether
drug-eluting balloons might enable a reduction in
the already low rate of major adverse cardiac events
found in these trials. Once this last question is
resolved, their treatment will be faced with less
heterogeneity, and bifurcations will not represent a
pending issue in future meetings.*Iñigo Lozano, MD, PhD
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in Bifurcations: The Remaining Variable to
Fit the Perfect EquationWe thank Dr. Lozano and colleagues for their interest
in our study (1). The CROSS and PERFECT studies
showed that any bifurcation stenting technique can
yield a good clinical outcome once the procedure is
optimally performed using intravascular ultrasound
and new-generation drug-eluting stents (DES) (1).
However, routine use of ﬁnal kissing balloon inﬂation
or the double-stent technique cannot contribute to
good clinical outcomes, potentially leading to unfa-
vorable angiographic outcomes. Therefore, our study
emphasized that the most important aspect of bifur-
cation stenting is to perform the optimal procedure
using a new-generation DES and not the selection of a
bifurcation stenting technique. Moreover, our study
results indicate that judgment of whether each side
branch (SB) should or should not be treated must be
made very judiciously. Given the ischemic threshold
reported by Hachamovitch et al. (2), above which
revascularization leads to a survival beneﬁt, SB
without functional signiﬁcance does not need to be
revascularized unless the blood ﬂow is compromised.
As indicated by Loh and Waksman (3), a drug-
coated balloon (DCB) may be used as an alternative
to conventional SB treatment. Despite the lack of
evidence, a DCB may be helpful for preventing
intimal growth caused by balloon injury without any
additional DES implantation. Nonetheless, there are
several prerequisites for DCBs to be used for SB
revascularization. Practically, DCBs of various sizes
should be developed to ﬁt a small SB. A recrossing
technique to minimize drug denudation should also
be investigated. Importantly, clinical evidence to
support the beneﬁt of DCBs for native vessels should
be accumulated. For now, DCBs are qualiﬁed as a
reliable option for revascularization of in-stent
restenosis (ISR) following bifurcation stenting (4).
Added to the previously implanted stents, repeatedly
implanted DES for bifurcation ISR lesions lead to
excessive stent layers, especially after using the
double-stent technique. However, DCB can prevent
neointimal hyperplasia with an antiproliferative drug
without additional stent implantation.
In conclusion, the functional evaluation of SB is of
paramount importance before determining its revas-
cularization. Once this is decided, stent optimization
